EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy - rationale and design of the EARLY hypertension registry

BMC Cardiovascular Disorders

Volumn 13, Issue , 2013, Pages

  Gitt, Anselm K ^a,b   Baumgart, Peter ^c   Bramlage, Peter ^d   Mahfoud, Felix ^e   Potthoff, Sebastian A ^f   Senges, Jochen ^a   Schneider, Steffen ^a   Buhck, Hartmut ^g   Schmieder, Roland E ^h  

^a Foundation Stiftung Institut für Herzinfarktforschung   (Germany)

^b KLINIKUM LUDWIGSHAFEN   (Germany)

^c Clemenshospital Munster   (Germany)

^d Institut fur Pharmakologie und Praventive Medizin   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^g MedCommTools (Medical Scientific Consultancy)   (Germany)

^h UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

ACE Inhibitors; Ambulatory Blood Pressure Measurement; Azilsartan; Blood Pressure; Central Systolic Blood Pressure; Follow up; Non Interventional; Ramipril

Indexed keywords

AZILSARTAN MEDOXOMIL; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; OLMESARTAN; PLACEBO; RAMIPRIL; VALSARTAN;

ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; HYPERTENSION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; REGISTER;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; OXADIAZOLES; PROSPECTIVE STUDIES; REGISTRIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879807532     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-13-46     Document Type: Article

References (19)

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360(9349):1903-1913.
2. Sharma AM, Wittchen HU, Kirch W, Pittrow D, Ritz E, Goke B, Lehnert H, Tschope D, Krause P, Hofler M, et al. High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens 2004, 22(3):479-486. 10.1097/00004872-200403000-00009, 15076152.
3. Ojima M, Igata H, Tanaka M, Sakamoto H, Kuroita T, Kohara Y, Kubo K, Fuse H, Imura Y, Kusumoto K, et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011, 336(3):801-808. 10.1124/jpet.110.176636, 21123673.
4. Kohara Y, Kubo K, Imamiya E, Wada T, Inada Y, Naka T. Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. J Med Chem 1996, 39(26):5228-5235. 10.1021/jm960547h, 8978851.
5. Noda M, Shibouta Y, Inada Y, Ojima M, Wada T, Sanada T, Kubo K, Kohara Y, Naka T, Nishikawa K. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem Pharmacol 1993, 46(2):311-318. 10.1016/0006-2952(93)90420-2, 8347154.
6. White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011, 57(3):413-420. 10.1161/HYPERTENSIONAHA.110.163402, 21282560.
7. Sica D, White WB, Weber MA, Bakris GL, Perez A, Cao C, Handley A, Kupfer S. Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring. J Clin Hypertens (Greenwich) 2011, 13(7):467-472.
8. Bakris GL, Sica D, Weber M, White WB, Roberts A, Perez A, Cao C, Kupfer S. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich) 2011, 13(2):81-88.
9. Rakugi H, Enya K, Sugiura K, Ikeda Y. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens Res 2012, 35(5):552-558. 10.1038/hr.2012.8, 3348575, 22278628.
10. Jones JD, Jackson SH, Agboton C, Martin TS. Azilsartan Medoxomil (Edarbi): The Eighth Angiotensin II Receptor Blocker. P T 2011, 36(10):634-640. 3278144, 22346296.
11. Bönner G, Bakris GL, Sica D, et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens 2013, [epub ahead of print].
12. Anderson VR, Perry CM, Robinson DM. Ramipril: a review of its use in preventing cardiovascular outcomes in high-risk patients. Am J Cardiovasc Drugs 2006, 6(6):417-432. 10.2165/00129784-200606060-00012, 17192135.
13. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342(3):145-153.
14. Steg PG, Lopez-Sendon J, Lopez De Sa E, Goodman SG, Gore JM, Anderson FA, Himbert D, Allegrone J, Van de Werf F, Investigators G. External validity of clinical trials in acute myocardial infarction. Arch Intern Med 2007, 167(1):68-73. 10.1001/archinte.167.1.68, 17210880.
15. Bramlage P, Wolf WP, Stuhr T, Fronk EM, Erdlenbruch W, Ketelhut R, Schmieder RE. Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice. Vasc Health Risk Manag 2010, 6:803-811. 2941791, 20859549.
16. Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008, 30(4):587-604. 10.1016/j.clinthera.2008.04.002, 18498909.
17. Roy J, Shah NR, Wood GC, Townsend R, Hennessy S. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study. J Clin Hypertens (Greenwich) 2012, 14(7):407-414.
18. Scholze J, Bramlage P, Trenkwalder P, Kreutz R. Efficacy and safety of a fixed-dose combination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure. Expert Opin Pharmacother 2011, 12(18):2771-2779. 10.1517/14656566.2011.626770, 21999703.
19. Mengden T, Hubner R, Bramlage P. Office and ambulatory blood pressure control with a fixed-dose combination of candesartan and hydrochlorothiazide in previously uncontrolled hypertensive patients: results of CHILI CU Soon. Vasc Health Risk Manag 2011, 7:761-769. 3253769, 22241950.